Transgene SA (EPA:TNG)

Market Cap	202.63M +131.6%
Revenue (ttm)	7.21M +13.5%
Net Income	-37.52M
EPS	-0.26
Shares Out	273.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65,202
Average Volume	72,576
Open	0.7820
Previous Close	0.7660
Day's Range	0.7400 - 0.7820
52-Week Range	0.5300 - 1.5000
Beta	0.73
RSI	39.92
Earnings Date	Mar 24, 2026

About Transgene

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastroi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1979
• Employees: 147
• Stock Exchange: Euronext Paris
• Ticker Symbol: TNG

Financial Performance

In 2025, Transgene's revenue was 7.21 million, an increase of 13.49% compared to the previous year's 6.35 million. Losses were -37.52 million, 10.5% more than in 2024.